---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-22-000041"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:38:42.796422+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q2 2022 net revenue up 21.5% YoY to $123.5M; GAAP EPS $0.33

## Summary
- Net revenues $123.5M for Q2 2022, up from $101.7M in Q2 2021 (21.5% increase).
- GAAP net income $17.3M ($0.33 diluted EPS) vs $7.8M ($0.16) in Q2 2021.
- Adjusted non-GAAP net income $20.7M ($0.39 diluted EPS) vs $10.6M ($0.21) in Q2 2021.
- CEO cites strong sales momentum; expects continued growth from ganirelix and vasopressin launch.

## SEC filing metadata
- accession: 0001297184-22-000041
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718422000041/0001297184-22-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718422000041/amph-20220808x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-22-000041
- JSON: https://secwatch.observer/filing/0001297184-22-000041.json
- Plain text: https://secwatch.observer/filing/0001297184-22-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.